Author:
Chi Mau-Shin,Hsieh Ping-Hsun,Huang Shu-Han,Hsu Ho-Chi,Chi Kwan-Hwa
Abstract
Abstract
Background
Radiation proctitis (RP) is a significant complication of pelvic radiation. Effective treatments for chronic RP are currently lacking. We report a case where chronic RP was successfully managed by metformin and butyrate (M-B) enema and suppository therapy.
Case presentation
A 70-year-old Asian male was diagnosed with prostate cancer of bilateral lobes, underwent definitive radiotherapy to the prostate of 76 Gy in 38 fractions and six months of androgen deprivation therapy. Despite a stable PSA nadir of 0.2 ng/mL for 10 months post-radiotherapy, he developed intermittent rectal bleeding, and was diagnosed as chronic RP. Symptoms persisted despite two months of oral mesalamine, mesalamine enema and hydrocortisone enema treatment. Transition to daily 2% metformin and butyrate (M-B) enema for one week led to significant improvement, followed by maintenance therapy with daily 2.0% M-B suppository for three weeks, resulting in continued reduction of rectal bleeding. Endoscopic examination and biopsy demonstrated a good therapeutic effect.
Conclusions
M-B enema and suppository may be an effective treatment for chronic RP.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Ferini G, Pergolizzi S. A ten-year-long update on radiation proctitis among prostate cancer patients treated with curative external beam radiotherapy. In vivo (Athens, Greece). 2021;35(3):1379–91.
2. Toita T, Kato S, Niibe Y, Ohno T, Kazumoto T, Kodaira T, et al. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys. 2012;82(1):e49-56.
3. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48(3):635–42.
4. Tandberg DJ, Oyekunle T, Lee WR, Wu Y, Salama JK, Koontz BF. Postoperative radiation therapy for prostate cancer: comparison of conventional versus hypofractionated radiation regimens. Int J Radiat Oncol Biol Phys. 2018;101(2):396–405.
5. Hasan S, Lazarev S, Garg M, Gozland R, Chang J, Hartsell W, et al. Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001–09 prospective registry trial. Prostate. 2023;83(9):850–6.